HUMALOG MIX 50/50 KWIKPEN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for HUMALOG MIX 50/50 KWIKPEN (HUMALOG MIX 50/50 KWIKPEN).
Insulin lispro is a rapid-acting insulin analog that lowers blood glucose by stimulating peripheral glucose uptake, especially in skeletal muscle and adipose tissue, and by inhibiting hepatic glucose production. It binds to the insulin receptor, activating tyrosine kinase signaling.
| Metabolism | Insulin lispro is primarily metabolized by insulin-degrading enzyme; metabolism results in inactive metabolites. |
| Excretion | Renal: 60-80% as metabolites; hepatic metabolism accounts for most of the remainder. Fecal excretion is minimal. |
| Half-life | 0.5-1 hour (insulin lispro); terminal half-life is approximately 1 hour. Clinically, the rapid clearance allows for flexible dosing timing relative to meals. |
| Protein binding | <10% bound to plasma proteins (insulin lispro has low protein binding). |
| Volume of Distribution | 0.26-0.44 L/kg (approximates extracellular fluid volume; clinical significance: distribution is rapid into peripheral tissues). |
| Bioavailability | Subcutaneous: 55-77% (variant due to injection site and technique; intact insulin lispro is absorbed rapidly). |
| Onset of Action | Subcutaneous: 15-30 minutes (rapid-acting insulin analog). |
| Duration of Action | Subcutaneous: 3-5 hours (shorter than regular human insulin; premixed formulation includes protamine suspension to extend duration). |
Subcutaneous injection: individualized dose based on metabolic needs, blood glucose monitoring, and prior insulin therapy. Typically administered within 15 minutes before meals or immediately after meals. Total daily dose: 0.5-1.0 units/kg/day in divided doses. For the mix 50/50, half as basal (intermediate-acting component) and half as bolus (rapid-acting component).
| Dosage form | INJECTABLE |
| Renal impairment | GFR 30-50 mL/min: reduce dose by 25% and monitor closely. GFR 15-29 mL/min: reduce dose by 50%. GFR <15 mL/min: avoid use or reduce dose by 75% with frequent monitoring due to increased risk of hypoglycemia. No specific dose recommendations for dialysis; use with caution. |
| Liver impairment | Child-Pugh Class A: no adjustment needed. Child-Pugh Class B: reduce dose by 25% and monitor glucose. Child-Pugh Class C: reduce dose by 50% or consider alternative therapy due to impaired gluconeogenesis and increased hypoglycemia risk. |
| Pediatric use | Children <3 years: safety not established. Children 3-11 years: initial total daily dose 0.5-1.0 units/kg/day divided into 2-3 doses, with 50% as intermediate-acting component. Children 12-18 years: same as adult dosing, individualized. Administer subcutaneously 15 minutes before meals. |
| Geriatric use |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for HUMALOG MIX 50/50 KWIKPEN (HUMALOG MIX 50/50 KWIKPEN).
| Breastfeeding | Insulin lispro is excreted into breast milk in negligible amounts, with an estimated M/P ratio of <1. It is considered safe for use during breastfeeding. However, it is not absorbed orally by the infant due to enzymatic degradation. |
| Teratogenic Risk | Insulin lispro does not cross the placenta in significant amounts. No increased risk of congenital anomalies has been associated with maternal insulin use. Poorly controlled diabetes carries risks such as spontaneous abortion, congenital malformations (especially neural tube defects and cardiac anomalies), and macrosomia. Human data do not indicate teratogenic risk. |
■ FDA Black Box Warning
Changes in insulin strength, manufacturer, type, or method of administration should be made under close medical supervision to prevent hypoglycemia.
| Serious Effects |
["Hypoglycemia","Hypersensitivity to insulin lispro or any product excipients"]
| Precautions | ["Hypoglycemia is the most common adverse effect","Accidental mix-ups between insulin products can occur","Changes in insulin dose may be needed during illness, stress, or changes in renal/hepatic function","Not for use in insulin pumps or for intravenous administration"] |
Loading safety data…
| Elderly patients >65 years: start with lower total daily dose (0.2-0.4 units/kg/day) due to increased risk of hypoglycemia and renal impairment. Titrate slowly with close glucose monitoring. Consider reduced meal-associated doses and avoid aggressive glycemic targets. |
| Fetal Monitoring | Monitor maternal blood glucose levels closely (targets per ADA guidelines). Assess fetal growth via ultrasound (weight, amniotic fluid index) in third trimester. Monitor for maternal hypoglycemia and hyperglycemia. Consider fetal echocardiography if glycemic control is suboptimal. |
| Fertility Effects | No adverse effects on fertility reported. Improved glycemic control in diabetic patients may restore fertility by promoting normal ovulation. |